Mikel Lipschitz
Mikel Lipschitz
PhD Candidate, Caltech
Verified email at caltech.edu
Title
Cited by
Cited by
Year
Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma
S George, D Miao, GD Demetri, D Adeegbe, SJ Rodig, S Shukla, ...
Immunity 46 (2), 197-204, 2017
2942017
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma
CD Carey, D Gusenleitner, M Lipschitz, MGM Roemer, EC Stack, E Gjini, ...
Blood, The Journal of the American Society of Hematology 130 (22), 2420-2430, 2017
1822017
Angiopoietin-2 as a biomarker and target for immune checkpoint therapy
X Wu, A Giobbie-Hurder, X Liao, C Connelly, EM Connolly, J Li, ...
Cancer immunology research 5 (1), 17-28, 2017
972017
Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity
CA Jacobson, B Hunter, P Armand, Y Kamihara, J Ritz, SJ Rodig, ...
Blood 132, 92, 2018
722018
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment
FZ Cader, RCJ Schackmann, X Hu, K Wienand, R Redd, B Chapuy, ...
Blood, The Journal of the American Society of Hematology 132 (8), 825-836, 2018
692018
Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity
CA Jacobson, BD Hunter, R Redd, SJ Rodig, PH Chen, K Wright, ...
Journal of Clinical Oncology 38 (27), 3095-3106, 2020
652020
The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4–positive T cells that are PD-1–negative
SS Patel, JL Weirather, M Lipschitz, A Lako, PH Chen, GK Griffin, ...
Blood 134 (23), 2059-2069, 2019
402019
The immune microenvironment in hormone Receptor–Positive breast cancer before and after preoperative chemotherapy
AG Waks, DG Stover, JL Guerriero, D Dillon, WT Barry, E Gjini, C Hartl, ...
Clinical Cancer Research 25 (15), 4644-4655, 2019
322019
Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
PH Chen, M Lipschitz, JL Weirather, C Jacobson, P Armand, K Wright, ...
JCI insight 5 (12), 2020
222020
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer
AK Mehta, EM Cheney, CA Hartl, C Pantelidou, M Oliwa, JA Castrillon, ...
Nature Cancer 2 (1), 66-82, 2021
152021
Evaluating the PD-1 axis and immune effector cell infiltration in oropharyngeal squamous cell carcinoma
JD Schoenfeld, E Gjini, SJ Rodig, RB Tishler, B Rawal, PJ Catalano, ...
International Journal of Radiation Oncology* Biology* Physics 102 (1), 137-145, 2018
132018
Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma
GK Griffin, JL Weirather, MGM Roemer, M Lipschitz, A Kelley, PH Chen, ...
Blood, The Journal of the American Society of Hematology 137 (10), 1353-1364, 2021
82021
Mass cytometry of Hodgkin lymphoma reveals a CD4 (+) exhausted T-effector and T-regulatory cell rich microenvironment
FZ Cader, RCJ Schackmann, X Hu, K Wienand, R Redd, B Chapuy, ...
Blood 132, 825-836, 2018
82018
Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30‐positive lymphoma with cutaneous presentation …
A Sawas, P Chen, G Vlad, M Lipschitz, M Abdul‐Hay, J Lue, C Deng, ...
Hematological Oncology 37, 314-316, 2019
62019
Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation …
A Sawas, H Elgedawe, G Vlad, M Lipschitz, PH Chen, SJ Rodig, JK Lue, ...
Blood 132, 2908, 2018
52018
Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment
SS Patel, M Lipschitz, GS Pinkus, JL Weirather, O Pozdnyakova, ...
Modern Pathology 33 (7), 1380-1388, 2020
42020
Analysis of CAR-T and immune cells within the tumor micro-environment of diffuse large B-cell lymphoma post CAR-T treatment by multiplex immunofluorescence
PH Chen, M Lipschitz, K Wright, P Armand, CA Jacobson, ZJ Roberts, ...
Blood 132, 678, 2018
42018
Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients
Y Boucher, AS Kumar, JM Posada, E Gjini, K Pfaff, M Lipschitz, A Lako, ...
NPJ Precision Oncology 5 (1), 1-6, 2021
32021
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
P Armand, YB Chen, RA Redd, RM Joyce, J Bsat, RW Merryman, ...
Blood 132, 1650, 2018
32018
Integrated genetic and topological analysis reveals a Hodgkin-like mechanism of immune escape in T-cell/histiocyte-rich large B-cell lymphoma
GK Griffin, MGM Roemer, M Lipschitz, J Weirather, CJ Pak, A Kelly, ...
Blood 132, 1579, 2018
22018
The system can't perform the operation now. Try again later.
Articles 1–20